12-Month Lobbying Summary - Organization

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Canada Country President

Registration Summary

Currently active - Last Updated: 2024-01-01

Who is lobbying?

Novartis Pharmaceuticals Canada Inc. (Address & business activities)

Mark Vineis, Canada Country President

Senior Officer in previous versions
- Pedro Ferreira, ad Interim Canada Country President
- Andrea Marazzi, Novartis Country President Canada

Government Funding

Did Novartis Pharmaceuticals Canada Inc. request or receive government funding within the last 12 months? No

Coalition Members Information

Novartis Pharmaceuticals Canada Inc. is a member of a coalition along with the following organizations:

Innovative Medicines Canada (Address information)
Life Sciences BC (Address information)

Direct Interests of the Lobbying Activity

Affiliates

Novartis Pharmaceuticals Canada Inc. has the following affiliates that could have a direct interest in the outcome of the lobbying activities:

Novartis AG (Address information)

Affiliates as entered in previous versions
Registration version: 35
- Sandoz Canada Inc. (Address information)

Other Affiliates

The activities of Novartis Pharmaceuticals Canada Inc. are not controlled or directed by another person or organization with a direct interest in the outcome of this undertaking

Contributors with a Direct Interest in the Outcome

No person or organization contributed over $1000CDN, within the preceding 12 months, toward the lobbying activity on behalf of Novartis Pharmaceuticals Canada Inc.:

What is being lobbied?

Subject Matter of the Lobbying Activities

Details Regarding the Identified Subject Matter

Will any of the lobbyists listed within this registration arrange a meeting between a public office holder and any other individual for the purpose of attempting to influence any of the matters listed below:

Yes

Specific Topics of Lobbying Communications	Intended Outcomes	Associated Subject Matters
CC on an email message to department staff regarding Health Canada Approval of an important new therapy.	Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health
Deliver a 'pipeline review' presentation to provide Pharmacare program management with details of products currently under development (or not yet available in Canada) for which Pharmaceutical, Laboratory & Blood Services Division (PLBSD) will be making future funding decisions.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals, Senior Citizens
Deliver a 'pipeline review' presentation to provide Pharmacare program management with details of products currently under development (or not yet available in Canada) for which Pharmaceutical Services Division will be making future funding decisions.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals
Discussions with BC government officials/organizations and elected representatives to obtain public reimbursement of Novartis' innovative pharmaceutical treatments for BC citizens that require publicly funded access to these treatments, through various BC government programs such as Pharmacare, Health Authorities, BC Cancer Agency, etc. And, to encourage the BC government to recognize the importance of Novartis investments in Research and Development to the development of BC's healthcare bioscience research ecosystem and to providing innovative approaches to management of the health care system.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals, Science and Technology, Senior Citizens
Discussions with BC government officials/organizations and elected representatives to obtain public reimbursement of Novartis' innovative treatments for BC citizens that require access to these treatments, through various BC government funded programs such as Pharmacare, Health Authorities, BC Cancer Agency, etc. And, to encourage the BC government to recognize the importance of Novartis investments in Research and Development to the development of BC's healthcare bioscience research ecosystem and to providing innovative approaches to management of the health care system.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Economic Development and Trade, Health, Hospitals
Meeting request to explore and understand BC Ministry of Health challenges, barriers, timelines and possible solutions to enable patients to be treated with innovative specialized therapies at sites in BC. (BC patients currently do not have access or are traveling to out-of-province jurisdictions to receive some innovative therapies.)	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health
Meetings with government officials regarding government funding to facilitate patient access to Novartis pharmaceutical treatments	Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health
Meeting with the Minister of Jobs, Economic Development and Innovation to discuss the BC Life Sciences Strategy and Novartis' role as a key partner in the province's bioscience ecosystem, including data partnerships, patient access to innovative medicines and expanded access to diagnostic equipment.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Economic Development and Trade, Health, Science and Technology
Request a meeting to discuss innovative program pioneered by the NHS (England) to address cardiovascular disease risk factor mitigation through a collaborative program created to identify and treat patients high risk for CVD due to elevated cholesterol levels that does not meet current Clinical Guideline standards as published by the Canadian Cardiovascular Congress. Enacting such a program in BC will impact health system resource use caused by the downstream impact of Cardiovascular disease; heart attack, stroke, etc.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals, Senior Citizens

Subject matter details in previous versions

Specific Topics of Lobbying Communications	Intended Outcomes	Associated Subject Matters
Follow up letter to June 5, 2023 meeting with the Minister of Jobs, Economic Development and Innovation during which we discussed the BC Life Sciences Strategy and Novartis' role as a key partner in the province's bioscience ecosystem, including data partnerships, patient access to innovative medicines (including the abscence of a drug named KESIMPTA from public listing) and expanded access to diagnostic equipment.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health

Gifts or benefits provided by the organization

Gifts or Benefits Provided to Public Officer Holders
Name	Gift or Benefit Description	Circumstance	Date Promised	Value Promised	Date Given	Value Given
No Records

Who is being lobbied?

Ministries/Provincial Entities

Fraser Health Authority
Health
Innovate BC
Jobs, Economic Development and Innovation
Member(s) of the BC Legislative Assembly
Office of the Premier
Providence Health Care Society
Provincial Health Services Authority
Vancouver Coastal Health Authority
Vancouver Island Health Authority

Who are the lobbyists?

In-house Lobbyists

Lobbyist

Contributions

Graham Anderson
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied or plans to lobby a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization, on or after 2020-09-21: No

Caroline Barber
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied or plans to lobby a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization, on or after 2020-09-21: Yes

Political: No
Sponsorship: No
Recall: No

Jeremy Chorney
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied or plans to lobby a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization, on or after 2020-09-21: Yes

Political: No
Sponsorship: No
Recall: No

Thea Discepola
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied or plans to lobby a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization, on or after 2020-09-21: Yes

Political: No
Sponsorship: No
Recall: No

Clayton Gilmore
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied or plans to lobby a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization, on or after 2020-09-21: No

Kate Jervis
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied or plans to lobby a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization, on or after 2020-09-21: No

Jordan Roumieu
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied or plans to lobby a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization, on or after 2020-09-21: No

Lobbyists in previous versions

In-house Lobbyists
Lobbyist	BC Former Public Office Holder Positions	Contributions
Andrea Marazzi	Former Public Office Holder in BC: No	Contributions: No
Andrea Marazzi	Former Public Office Holder in BC: No	Contributions: No
Michael McLean	Former Public Office Holder in BC: No	Contributions: No
Thu Parmar	Former Public Office Holder in BC: No	Contributions: No

Registration number: 10154-2301
View all registrations versions

Lobbying Activity Reports

What lobbying activities have taken place in the last 12 months?

What lobbying activities have taken place in the last 12 months?
Date	Arranging a Meeting	Lobbyists	Senior Public Office Holder, Position Title \| Ministry/Provincial Entity	Subject Matters
2023-06-22	No	Caroline Barber , Jeremy Chorney , Andrea Marazzi	Brenda Bailey, Minister of Jobs, Economic Development and Innovation \| Minister's Office, Jobs, Economic Development and Innovation Nina Cagic, Director, Internal Trade and Investment Operations \| Jobs, Economic Development and Innovation Paul Pawlowski, Assistant Deputy Minister, Investment Division \| Jobs, Economic Development and Innovation	View
2023-06-05	No	Caroline Barber , Jeremy Chorney , Andrea Marazzi	Brenda Bailey, Minister of Jobs, Economic Development and Innovation \| Minister's Office, Jobs, Economic Development and Innovation Terry Harrison, Chief of Staff \| Minister's Office, Jobs, Economic Development and Innovation Paul Pawlowski, Assistant Deputy Minister, Investment Division \| Jobs, Economic Development and Innovation	View

View all Lobbying Activity Reports

Novartis Pharmaceuticals Canada Inc. - Address & business activities

Address:

700 St-Hubert Street
Suite 100
Montreal, QC H2Y 0C1
Canada

Telephone number: 514-631-6775

Contact information in previous versions
- 700 St-Hubert Street, Suite 100
  Montreal, QC H2Y 0C1
  Canada
  
  Telephone number: 780-288-1286
- 385 Boul Bouchard.
  Dorval, QC H9S 1A9
  Canada
  
  Telephone number: 514-631-6775
- 385 Boul Bouchard.
  Dorval, QC H9S 1A9
  Canada
  
  Telephone number: 604-218-9838
  
  Fax number: 514-631-0307
- 22093 46B Avenue
  
  Langley, BC V2Z 1A9
  Canada
  
  Telephone number: 604-218-9838
  
  Fax number: 514-631-0307
- 385 Boul Bouchard
  
  Dorval, BC H9S 1N9
  Canada
  
  Telephone number: 514-631-6775
  
  Fax number: 514-631-0307
- 385 Boul Bouchard
  
  Dorval, QC H9S 1N9
  Canada
  
  Telephone number: 514-631-6775
  
  Fax number: 514-631-0307
- 22093-46B Avenue
  
  Langley, BC V2Z 1A9
  Canada
  
  Telephone number: 604-218-9838
  
  Fax number: 604-532-8724

Description of Activities:
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative medicines and procedures to improve the health and well-being of Canadians. Novartis is a leading investor in pharmaceutical research and development worldwide and in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 900 people and has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca.

Descriptions of the organization's activity in previous versions:
- Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative medicines and procedures to improve the health and well-being of Canadians. Novartis is a leading investor in pharmaceutical research and development worldwide and in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people and has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca.
- Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative medicines and procedures to improve the health and well-being of Canadians. Novartis is a leading investor in pharmaceutical research and development worldwide and in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people and has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca.
- Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative health care products and medicines to improve the well-being of Canadians. Novartis is a leading investor in pharmaceutical research and development worldwide and in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people and has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca.
- Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative health care products and medicines to improve the well-being of Canadians. Novartis is a leading investor in pharmaceutical research and development worldwide and in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. It has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca.
- Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of Canadians. Novartis is a leading investor in pharmaceutical research and development worldwide and in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. It has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca.
- Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. Novartis is a leading investor in pharmaceutical research and development worldwide and in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. It has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca.
- Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2013, the company invested in the range of ~$100 million in research and development in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. It has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca. Novartis Products include; Pharmaceuticals, Vaccines, Consumer Health products, Veterinary medicines, and Eye Care products
- Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2013, the company invested in the range of ~$100 million in research and development in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. It has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca. Novartis Products include; Pharmaceuticals, Vaccines, Consumer Health products, Veterinary medicines, and Eye Care products
- Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2013, the company invested in the range of ~$100 million in research and development in Canada. PMPRB has reported that Canadian R&D investments by Novartis was 12.6% of sales in 2012, increased from 11.4% in 2011. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. It has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca. Novartis Products include; Pharmaceuticals, Vaccines, Consumer Health products, Veterinary medicines, and Eye Care products
- Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2011, the company invested close to $100 million in research and development in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. It was named for the seventh time as one of the "50 Best Employers in Canada" for 2011. For further information, please visit www.novartis.ca. Novartis Products include; Pharmaceuticals, Vaccines, Consumer Health, Veterinary medicines,
- Pharmaceutical Research & Development, Manufacturing, Sales

Date Modified:: 2024-01-29

Menus

www.lobbyistsregistrar.bc.ca

12-Month Lobbying Summary - Organization

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Canada Country President

Who is lobbying?

Novartis Pharmaceuticals Canada Inc. (Address & business activities)

Government Funding

Coalition Members Information

Novartis Pharmaceuticals Canada Inc. is a member of a coalition along with the following organizations:

Direct Interests of the Lobbying Activity

Affiliates

Other Affiliates

Contributors with a Direct Interest in the Outcome

What is being lobbied?

Details Regarding the Identified Subject Matter

Gifts or benefits provided by the organization

Who is being lobbied?

Ministries/Provincial Entities

Who are the lobbyists?

What lobbying activities have taken place in the last 12 months?

12-Month Lobbying Summary - Organization

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Canada Country President

Novartis Pharmaceuticals Canada Inc. (Address & business activities)

Government Funding

Coalition Members Information

Novartis Pharmaceuticals Canada Inc. is a member of a coalition along with the following organizations:

Direct Interests of the Lobbying Activity

Affiliates

Other Affiliates

Contributors with a Direct Interest in the Outcome

Details Regarding the Identified Subject Matter

Gifts or benefits provided by the organization

Ministries/Provincial Entities

Novartis Pharmaceuticals Canada Inc. - Address & business activities

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Canada Country President

Innovative Medicines Canada

Novartis AG

Life Sciences BC

Sandoz Canada Inc.